These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 31997565)

  • 21. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
    Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
    Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies.
    Singh N
    J Clin Virol; 2006 Apr; 35(4):474-7. PubMed ID: 16406798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pharmacist-driven antimicrobial stewardship intervention targeting cytomegalovirus viremia in ambulatory solid organ transplant recipients.
    Wang N; Athans V; Neuner E; Bollinger J; Spinner M; Brizendine K
    Transpl Infect Dis; 2018 Dec; 20(6):e12991. PubMed ID: 30184302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
    Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
    Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.
    Monforte V; Sintes H; López-Gallo C; Delgado M; Santos F; Zurbano F; Solé A; Gavaldá J; Borro JM; Redel-Montero J; Cifrian JM; Pastor A; Román A; Ussetti P
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28294487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
    Hodson EM; Craig JC; Strippoli GF; Webster AC
    Cochrane Database Syst Rev; 2008 Apr; (2):CD003774. PubMed ID: 18425894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
    Torres-Madriz G; Boucher HW
    Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The development and implementation of stewardship initiatives to optimize the prevention and treatment of cytomegalovirus infection in solid-organ transplant recipients.
    Jorgenson MR; Descourouez JL; Schulz LT; Goldrosen KA; Rice JP; Redfield RR; Saddler CM; Smith JA; Mandelbrot DA
    Infect Control Hosp Epidemiol; 2020 Sep; 41(9):1068-1074. PubMed ID: 32456718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer risk associated with cytomegalovirus infection among solid organ transplant recipients in the United States.
    Geris JM; Spector LG; Pfeiffer RM; Limaye AP; Yu KJ; Engels EA
    Cancer; 2022 Nov; 128(22):3985-3994. PubMed ID: 36126024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
    Mabilangan C; Preiksaitis J; Cervera C;
    Transpl Infect Dis; 2018 Oct; 20(5):e12964. PubMed ID: 29981174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection.
    Benmarzouk-Hidalgo OJ; Cordero E; Martín-Peña A; García-Prado E; Gentil MA; Gomez-Bravo MA; Barrera-Pulido L; Cisneros JM; Perez-Romero P
    Antivir Ther; 2009; 14(5):641-7. PubMed ID: 19704166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention and Treatment of Cytomegalovirus Infections in Solid Organ Transplant Recipients.
    Koval CE
    Infect Dis Clin North Am; 2018 Sep; 32(3):581-597. PubMed ID: 30146024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S; Faulds D
    Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
    Bruminhent J; Rotjanapan P; Watcharananan SP
    Transplant Proc; 2017 Jun; 49(5):1048-1052. PubMed ID: 28583524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Incidence and Effect of Cytomegalovirus Disease on Mortality in Transplant Recipients and General Population: Real-world Nationwide Cohort Data.
    Han SH; Yoo SG; Do Han K; La Y; Kwon DE; Lee KH
    Int J Med Sci; 2021; 18(14):3333-3341. PubMed ID: 34400903
    [No Abstract]   [Full Text] [Related]  

  • 37. A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients.
    Suresh S; Lee BE; Robinson JL; Akinwumi MS; Preiksaitis JK
    Pediatr Transplant; 2016 Nov; 20(7):970-980. PubMed ID: 27565955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.
    Rittà M; Costa C; Solidoro P; Sidoti F; Libertucci D; Boffini M; Rinaldi M; Baldi S; Cavallo R
    Antiviral Res; 2015 Jan; 113():19-26. PubMed ID: 25446337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of electronic health record-based, pharmacist-driven valganciclovir dose optimization in solid organ transplant recipients.
    Hensler D; Richardson CL; Brown J; Tseng C; DeCamp PJ; Yang A; Pawlowski A; Ho B; Ison MG
    Transpl Infect Dis; 2018 Apr; 20(2):e12849. PubMed ID: 29360250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of cytomegalovirus infection in solid organ transplantation.
    Kotton CN
    Nat Rev Nephrol; 2010 Dec; 6(12):711-21. PubMed ID: 20978468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.